Hypertension Susceptibility Loci Are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors

Overview

Journal Sci Rep

Specialty Science

Date 2017 Aug 31

PMID 28851949

Citations 17

Authors

Michelle A T Hildebrandt

Monica Reyes

Xifeng Wu

Xia Pu

Kara A Thompson

Jianzhong Ma

Andrew P Landstrom

Alanna C Morrison

Joann L Ater

Affiliations

Soon will be listed here.

Abstract

Anthracycline-based chemotherapy is associated with dose-dependent, irreversible damage to the heart. Childhood cancer survivors with hypertension after anthracycline exposure are at increased risk of cardiotoxicity, leading to the hypothesis that genetic susceptibility loci for hypertension may serve as predictors for development of late cardiotoxicity. Therefore, we determined the association between 12 GWAS-identified hypertension-susceptibility loci and cardiotoxicity in a cohort of long-term childhood cancer survivors (N = 108) who received anthracyclines and were screened for cardiac function via echocardiograms. Hypertension-susceptibility alleles of PLCE1:rs9327264 and ATP2B1:rs17249754 were significantly associated with cardiotoxicity risk conferring a protective effect with a 64% (95% CI: 0.18-0.76, P = 0.0068) and 74% (95% CI: 0.07-0.96, P = 0.040) reduction in risk, respectively. In RNAseq experiments of human induced pluripotent stem cell (iPSC) derived cardiomyocytes treated with doxorubicin, both PLCE1 and ATP2B1 displayed anthracycline-dependent gene expression profiles. In silico functional assessment further supported this relationship - rs9327264 in PLCE1 (P = 0.0080) and ATP2B1 expression (P = 0.0079) were both significantly associated with daunorubicin IC values in a panel of lymphoblastoid cell lines. Our findings demonstrate that the hypertension-susceptibility variants in PLCE1 and ATP2B1 confer a protective effect on risk of developing anthracycline-related cardiotoxicity, and functional analyses suggest that these genes are influenced by exposure to anthracyclines.

Citing Articles

Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.

Raisi-Estabragh Z, Murphy A, Ramalingam S, Scherrer-Crosbie M, Lopez-Fernandez T, Reynolds K JACC CardioOncol. 2024; 6(5):631-654.

PMID: 39479317 PMC: 11520216. DOI: 10.1016/j.jaccao.2024.07.017.

Settling the score: what composite measures of social determinants tell us about hypertension risk.

Letsou W JNCI Cancer Spectr. 2024; 8(5).

PMID: 39222406 PMC: 11368122. DOI: 10.1093/jncics/pkae065.

Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci.

Stafford L, Tang X, Brandt A, Ma J, Banchs J, Livingston J Pharmacogenomics J. 2024; 24(4):21.

PMID: 38951505 PMC: 11824427. DOI: 10.1038/s41397-024-00343-0.

Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes.

Fonoudi H, Jouni M, Cejas R, Magdy T, Blancard M, Ge N JACC CardioOncol. 2024; 6(1):38-50.

PMID: 38510289 PMC: 10950437. DOI: 10.1016/j.jaccao.2023.11.008.

Anthracycline Toxicity: Light at the End of the Tunnel?.

Cejas R, Petrykey K, Sapkota Y, Burridge P Annu Rev Pharmacol Toxicol. 2023; 64():115-134.

PMID: 37788492 PMC: 11260185. DOI: 10.1146/annurev-pharmtox-022823-035521.

References

Wang X, Sun C, Quinones-Lombrana A, Singh P, Landier W, Hageman L . CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study. J Clin Oncol. 2016; 34(8):863-70. PMC: 5070560. DOI: 10.1200/JCO.2015.63.4550. View

Zhang L, Malik S, Pang J, Wang H, Park K, Yule D . Phospholipase Cε hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell. 2013; 153(1):216-27. PMC: 3615249. DOI: 10.1016/j.cell.2013.02.047. View

Johnson A, Handsaker R, Pulit S, Nizzari M, ODonnell C, de Bakker P . SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 2008; 24(24):2938-9. PMC: 2720775. DOI: 10.1093/bioinformatics/btn564. View

Westra H, Arends D, Esko T, Peters M, Schurmann C, Schramm K . Cell Specific eQTL Analysis without Sorting Cells. PLoS Genet. 2015; 11(5):e1005223. PMC: 4425538. DOI: 10.1371/journal.pgen.1005223. View

Bers D . Cardiac sarcoplasmic reticulum calcium leak: basis and roles in cardiac dysfunction. Annu Rev Physiol. 2013; 76:107-27. DOI: 10.1146/annurev-physiol-020911-153308. View

Fujiwara A, Hirawa N, Fujita M, Kobayashi Y, Okuyama Y, Yatsu K . Impaired nitric oxide production and increased blood pressure in systemic heterozygous ATP2B1 null mice. J Hypertens. 2014; 32(7):1415-23. DOI: 10.1097/HJH.0000000000000206. View

Blanco J, Sun C, Landier W, Chen L, Esparza-Duran D, Leisenring W . Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol. 2011; 30(13):1415-21. PMC: 3383117. DOI: 10.1200/JCO.2011.34.8987. View

Fukami K . Structure, regulation, and function of phospholipase C isozymes. J Biochem. 2002; 131(3):293-9. DOI: 10.1093/oxfordjournals.jbchem.a003102. View

Visscher H, Ross C, Rassekh S, Barhdadi A, Dube M, Al-Saloos H . Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2011; 30(13):1422-8. DOI: 10.1200/JCO.2010.34.3467. View

10.

Smrcka A, Brown J, Holz G . Role of phospholipase Cε in physiological phosphoinositide signaling networks. Cell Signal. 2012; 24(6):1333-43. PMC: 3325758. DOI: 10.1016/j.cellsig.2012.01.009. View

11.

Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, DAscenzo F, Malavasi V . Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013; 112(12):1980-4. DOI: 10.1016/j.amjcard.2013.08.026. View

12.

Xiang S, Ouyang K, Yung B, Miyamoto S, Smrcka A, Chen J . PLCε, PKD1, and SSH1L transduce RhoA signaling to protect mitochondria from oxidative stress in the heart. Sci Signal. 2013; 6(306):ra108. PMC: 4035240. DOI: 10.1126/scisignal.2004405. View

13.

Ward L, Kellis M . HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2011; 40(Database issue):D930-4. PMC: 3245002. DOI: 10.1093/nar/gkr917. View

14.

Robison L, Hudson M . Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer. 2013; 14(1):61-70. PMC: 6425479. DOI: 10.1038/nrc3634. View

15.

Sirenko O, Cromwell E, Crittenden C, Wignall J, Wright F, Rusyn I . Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity. Toxicol Appl Pharmacol. 2013; 273(3):500-7. PMC: 3900303. DOI: 10.1016/j.taap.2013.09.017. View

16.

Borlak J, Thum T . Hallmarks of ion channel gene expression in end-stage heart failure. FASEB J. 2003; 17(12):1592-608. DOI: 10.1096/fj.02-0889com. View

17.

Wang X, Liu W, Sun C, Armenian S, Hakonarson H, Hageman L . Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. J Clin Oncol. 2014; 32(7):647-53. PMC: 3927733. DOI: 10.1200/JCO.2013.50.3557. View

18.

Bers D . Cardiac excitation-contraction coupling. Nature. 2002; 415(6868):198-205. DOI: 10.1038/415198a. View

19.

Brini M, Carafoli E . The plasma membrane Ca²+ ATPase and the plasma membrane sodium calcium exchanger cooperate in the regulation of cell calcium. Cold Spring Harb Perspect Biol. 2011; 3(2). PMC: 3039526. DOI: 10.1101/cshperspect.a004168. View

20.

Gamazon E, Duan S, Zhang W, Huang R, Kistner E, Dolan M . PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics. 2010; 20(4):269-73. PMC: 2914089. DOI: 10.1097/FPC.0b013e328337b8d6. View